Trial Profile
A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary)
- Indications Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Endometrial cancer; Gallbladder cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Prostate cancer; Sarcoma; Solid tumours; Urogenital cancer
- Focus Therapeutic Use
- 04 Mar 2023 Status changed from suspended to completed.
- 05 Dec 2022 Results (n=30) assess the antitumor activity of adavosertib in patients with CCNE1-amplified, advanced refractory solid tumors published in the Journal of Clinical Oncology
- 01 Oct 2022 Planned End Date changed from 30 Sep 2022 to 30 Sep 2023.